08.05.2013 | Francesco M Carpi; Silvia Vincenzetti; Jessica Ubaldi; Stefania Pucciarelli; Valeria Polzonetti; Daniela ..., Pharmacogenomics, 2013

Aim: To assess the distribution of CDA activity from whole blood of 142 healthy subjects, determining its main predictors among genetic (six CDA SNPs) and physiological factors (age and gender). Moreover, we performed a kinetic study of the two CDA protein variants (Q27 and K27) determined by ...

mehr

08.05.2013 | Matthew T Oetjens; Joshua C Denny; Marylyn D Ritchie; Niloufar B Gillani; Danielle M Richardson; Nicole A ..., Pharmacogenomics, 2013

Background: The ADME Core Panel assays 184 variants across 34 pharmacogenes, many of which are difficult to accurately genotype with standard multiplexing methods. Methods: We genotyped 326 frequently medicated individuals of European descent in Vanderbilt’s biorepository linked to ...

mehr

08.05.2013 | Orna Levran; Einat Peles; Matthew Randesi; Xu Shu; Jurg Ott; Pei-Hong Shen; Miriam Adelson; Mary Jeann ..., Pharmacogenomics, 2013

Aim: The interindividual variability in the dose required for effective methadone maintenance treatment (MMT) for opioid addiction may be influenced in part by genetic variations in genes encoding pharmacodynamic factors of methadone. This study was conducted to identify some of these ...

mehr

08.05.2013 | Batoul Sadat Haerian; Monir Sadat Haerian, Pharmacogenomics, 2013

The OPRM1 gene encodes the µ-opioid receptor, which is the primary site of action of most opioids. Several studies and three meta-analyses have examined a possible link between the exonic OPRM1 A118G (rs1799971) polymorphism and opioid dependence; however, results have been inconclusive. ...

mehr

08.05.2013 | Julie A Johnson; Amanda R Elsey; Michael J Clare-Salzler; David Nessl; Michael Conlon; David R Nelson, Pharmacogenomics, 2013

The University of Florida and Shands Hospital recently launched a genomic medicine program focused on the clinical implementation of pharmacogenetics called the Personalized Medicine Program. We focus on a pre-emptive, chip-based genotyping approach that is cost effective, while providing ...

mehr

08.05.2013 | André BP van Kuilenburg; Jan Gerard Maring, Pharmacogenomics, 2013

5-fluorouracil (5-FU) remains the cornerstone of all currently applied regimens for the treatment of patients with cancers of the gastrointestinal tract, breast, and head and neck. Unfortunately, a large variation in the clearance of 5-FU has been observed between patients, suggesting that ...

mehr

08.05.2013 | Pharmacogenomics, 2013

Pharmacogenomics , May 2013, Vol. 14, No. 7, Pages 711-714.

mehr

08.05.2013 | Anke Tönjes; Peter Kovacs, Pharmacogenomics, 2013

The kidney has attracted the attention of diabetologists as an organ involved in the regulation of glucose homeostasis not only by gluconeogenesis, but also by renal glucose excretion. Sodium–glucose cotransporters (SGLTs), particularly SGLT2, are responsible for reabsorption of up to 99% of ...

mehr

08.05.2013 | Brian Murray; Emily Hawes; Ruth-Ann Lee; Robert Watson; Mary W Roederer, Pharmacogenomics, 2013

Advances in the management of patients after solid organ transplantation have led to dramatic decreases in rates of acute rejection, but long-term graft and patient survival have remained unchanged. Individualized therapy after transplant will ideally provide adequate immunosuppression while ...

mehr

08.05.2013 | Pharmacogenomics, 2013

Pharmacogenomics , May 2013, Vol. 14, No. 7, Pages 845-845.

mehr